Perrigo Co.’s Opill received U.S. clearance for over-the-counter use, making it the first daily oral birth-control product to be available without a prescription in the U.S.
The decision released Thursday by the U.S. Food and Drug Administration widens access to the drug by removing substantial barriers to obtaining oral contraception, such as inability to get a doctor’s appointment.
Shares of Perrigo rose as much as 5.8% at the New York market open, the most intraday since May 10.
